245 results
8-K
EX-10.1
j4k1oq7v 6p9u4jqmp
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
EX-10.3
kvtq0webrdw5trp3ewx
29 Feb 24
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.2
v8bez5615r ls5etw
29 Feb 24
Departure of Directors or Certain Officers
4:30pm
8-K/A
EX-10.1
o4ql169i9atkchwe
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K/A
gapw7g5vixdl5esmjdai
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
424B5
e775u5svpr eq66d5
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
EX-99.1
6vl5n44vq dg8r9y
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-10.1
50trjo1q3vs 0thqn
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-99.1
trfj451m53 akevw4
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
xcwfcs
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-1.1
xnes05n
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm